Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Methods. 2019 Oct 25;177:50–57. doi: 10.1016/j.ymeth.2019.10.010

Figure 2. Characterization of MSC-Derived MVs.

Figure 2.

A) Western blotting of MSC-derived MVs for common EV markers i.e. CD81, TSG101 and Calnexin. B) Flow cytometry analysis of CD9, CD63 and CD81 expression on MSC derived MVs captured onto anti-CD63-coated beads. C) Transmission electron microscopy image of MSC MVs. D) Representation of particle size (nm) and concentration (particles/ml) analyzed using nanoparticle tracking analysis (NTA).